Insights

Strategic focus ImaginAb is a clinical stage, revenue-generating biotech with a lead imaging candidate, CD8 ImmunoPET, in Phase II and licensed for use in immunotherapy trials, signaling strong upside in imaging partnerships and co-development opportunities with oncology players.

Acquisition impact Recent acquisition by Telix Pharmaceuticals of ImaginAb’s pipeline and platform suggests a potential post-merger pivot toward imaging-led assets; sales discussions can leverage Telix’s network and capacity for collaboration on radiopharmaceuticals and theranostics.

Theranostics potential ImaginAb’s minibody and cys-diabody radiopharmaceutical platforms, plus ongoing development of IAB56/IAB57, indicate opportunities to upsell radiopharmaceutical therapy collaborations and companion diagnostics with pharma partners seeking integrated imaging and treatment solutions.

Clinical trial demand With the CD8 ImmunoPET asset being licensed for use in multiple oncology immunotherapy trials, there is a ready market for expanding access, co-development, or out-licensing deals to sponsors running large immuno-oncology programs.

Partner network Existing collaborations with CROs like Oncodesign and strategic investments from Innoviva demonstrate openness to partnership and investment; targeted outreach to pharma biotech B2B teams managing later-stage trials and radiopharmaceutical portfolios could unlock near-term deals.

Similar companies to ImaginAb

ImaginAb Tech Stack

ImaginAb uses 8 technology products and services including Sage Intacct, LinkedIn Ads, Amazon Web Services, and more. Explore ImaginAb's tech stack below.

Media & News

ImaginAb's Email Address Formats

ImaginAb uses at least 3 email formats:
ImaginAb Email FormatsExamplePercentage
FLast@imaginab.comJDoe@imaginab.com
54%
First@imaginab.comJohn@imaginab.com
36%
Last@imaginab.comDoe@imaginab.com
10%

Frequently Asked Questions

What is ImaginAb's phone number?

Minus sign iconPlus sign icon
You can contact ImaginAb's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is ImaginAb's official website and social media links?

Minus sign iconPlus sign icon
ImaginAb's official website is imaginab.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does ImaginAb generate?

Minus sign iconPlus sign icon
As of October 2026, ImaginAb's annual revenue is estimated to be $1M - $10M.

What is ImaginAb's SIC code and NAICS code?

Minus sign iconPlus sign icon
ImaginAb's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does ImaginAb have currently?

Minus sign iconPlus sign icon
As of October 2026, ImaginAb has approximately 12 employees across 1 continents, including North America. Key team members include Chief Executive Officer: M. C., Chief Marketing Officer: R. K. and Vice President Of Business Development: A. A. Explore ImaginAb's employee directory with LeadIQ.

What industry does ImaginAb belong to?

Minus sign iconPlus sign icon
ImaginAb operates in the Biotechnology Research industry.

What technology does ImaginAb use?

Minus sign iconPlus sign icon
ImaginAb's tech stack includes Sage Intacct, LinkedIn Ads, Amazon Web Services, WordPress, Mailchimp, Microsoft 365, ZoomInfo and DocuSign.

What is ImaginAb's email format?

Minus sign iconPlus sign icon
ImaginAb's email format typically follows the pattern of FLast@imaginab.com. Find more ImaginAb email formats with LeadIQ.

How much funding has ImaginAb raised to date?

Minus sign iconPlus sign icon
As of October 2026, ImaginAb has raised $60M in funding. The last funding round occurred on Jun 03, 2021 for $13M.

When was ImaginAb founded?

Minus sign iconPlus sign icon
ImaginAb was founded in 2007.
ImaginAb logo

ImaginAb

Biotechnology ResearchCalifornia, United States11-50 Employees

ImaginAb is a clinical-stage global biotechnology company focused on developing imaging agents and radiopharmaceutical therapies, built on minibody and cys-diabody platforms. Its lead candidate, 89Zr crefmirlimab berdoxam, known as CD8 ImmunoPET, is in Phase II and has been licensed by multiple pharmaceutical and biotech firms for use in imaging within immunotherapy trials, primarily in oncology. The company serves pharmaceutical and biotech customers seeking new imaging tools to support cancer immunotherapy programs.

Based in Inglewood, California, the company operates within the biotechnology research sector with a focus on diagnostics and radiopharmaceuticals for cancer. In January 2025, Telix Pharmaceuticals Limited completed the acquisition of ImaginAb, a move that aligns with continued development of ImaginAb's lead imaging asset, CD8 ImmunoPET, which is in Phase II trials.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2007
Employees
11-50

Section iconFunding & Financials

  • $60M

    ImaginAb has raised a total of $60M of funding over 5 rounds. Their latest funding round was raised on Jun 03, 2021 in the amount of $13M as a Venture Round.

  • $1M - $10M

    ImaginAb's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.